Pharmacy benefit managers are the middlemen in the prescription drug market. The Federal Trade Commission reports the revenue of four PBMs exceeds $1 trillion and they control 86% of the market.
In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus.
In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus.
The lawsuit comes just after Cigna/Express Scripts filed a legal pre-emptive strike of its own, seeking a retraction of the FTC's report on the sector and accusing the financial regulator of ...
An arbitrator has determined Prime Therapeutics violated federal and state antitrust laws against the AIDS Healthcare ...
As the rising cost of insulin continues to make it difficult for so many diabetic patients to receive life-saving care, ...
Oil and gas production in the United States is hitting record highs, easily outpacing consumption growth and fueling an export boom that in 2020 achieved the country’s first trade surplus in energy ...
Drugmakers hope to see efforts that focus more on cracking down on pharmacy benefit managers while promoting drug innovation ...
Evercore ISI has updated its outlook on CVS Health (NYSE:CVS) shares, raising the price target from $60.00 to $65.00 while ...
In a recent antitrust arbitration ruling, Prime Therapeutics, a pharmacy benefit manager (PBM) owned by 19 Blue Cross and ...
Pharmacy benefit management giant Express Scripts unveiled several steps it's taking to boost transparency and mitigate high ...
Two Democrats at FTC declined to vote Ferguson criticized dissenting Democrat for opposing Trump Vote surfaces larger disagreement over FTC independence Jan 24 (Reuters) - U.S. Federal Trade ...